About FSHD Canada Foundation

FSHD clinical trials are coming to Canada – get registered here: Canadian Neuromuscular Disease Registry

Move To A Cure...
A Cure To Move

Funding research to help find a cure for Canadians who suffer from FSHD.

Muscle Regeneration: EPIRIUM

Test period: February 2024 – March 2024 Investigator: Epirium: Micah Webster, PhD Myologica: Ramzi Khairallah, PhD Lay abstract Muscle Regeneration Projects We don’t have a cure for FSHD – yet.…

Read More

Muscle Regeneration: ECM/MBV

Test period: November 2023 to January 2024 Investigator: University of Pittsburgh: Stephen Badylak, PhD & George Hussey, PhD Myologica: Ramzi Khairallah, PhD Lay abstract Muscle Regeneration Projects We don’t have…

Read More

Muscle Regeneration: SATELLOS

Test period: December 2023 – March 2024 Investigator: Satellos: Phil Lambert, PhD Myologica: Ramzi Khairallah, PhD Lay abstract Muscle Regeneration Projects We don’t have a cure for FSHD – yet.…

Read More

Srideep Dey

Kitchener, ON

I was diagnosed with fshd at the age of 10, now I'm 23. I also face the same difficulties, among which climbing staircase is the worst, and I am scared…

Read More

Shanon

Spruce Grove, AB

I was a diagnosed at the age of 13 (1983). Neither of my parents have nor carry the gene. There is no family history. When I was 23, I had…

Read More

John Mora

Toronto, ON

Good evening, my name is John. I was diagnosed with FSHD Muscular Dystrophy on January of 2015. Before my diagnosis I used to train MMA and kickboxing, live a normal…

Read More

Our Mission

The singular goal of the FSHD Canada Foundation is to help find a cure — as soon as possible — for Canadians who suffer with FSHD.

To accomplish this the Foundation aims to reach out to all Canadians to make them aware of what is going on in FSHD research and to solicit financial support for the critical research required to find a cure. The Foundation will then use these funds to support FSHD research — in Canada and around the world.

Learn More

What is FSHD?

Facioscapulohumeral muscular dystrophy or FSHD is the most prevalent of the nine primary types of muscular dystrophy affecting adults and children. Muscular dystrophy in general connotes a genetic, hereditary muscle disease that causes progressive muscle weakness. FSHD is also broadly characterized as a neuromuscular disease (NMD), as muscular dystrophy is a subset of NMD. Muscular dystrophies are alike in that they cause progressive skeletal muscle weakness, defects in the biochemical, physical and structural components of muscle, and the death of muscle cells and tissue. However, researchers believe that the causes of each of the muscular dystrophies are not necessarily the same.

Learn More

https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca